TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02278094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue Muscle Trainer (TMT)
Description: Subject will be instructed to compress the Iowa Oral Performance Instrument (IOPI) IOPI's bulb using tongue in three directions (anterior and both lateral sides). Then, hold 30-35 seconds each time. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold Inspiratory Muscle Trainer (TIMT)
Description: Resistance of the TIMT devices will be set from 30% of the maximum inspiratory pressure. Nose clip follow by normal breathing. Seal the mouth to the device's mouth piece then inhale through the device. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Walking Exercise
Description: Subjects will be encouraged to perform walking exercise in the field 10000 steps/ 60 minutes daily then continue three to five times a week during first months. Followed by 12500 steps and 15000steps per day during the second and third months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: CPAP regular therapy per day (use ≥ 4 h/day) then continue three to five times a week for a total of 3 months.
Study: NCT03025906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Description: In the PB group, a loading dose of 20 mg/kg (may give an additional 10 mg/kg) begins at a rate of 50 mg/min followed by IV 100 mg q6 h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: In the VPA group, a loading dose of 30 mg/kg (may give an additional 15 mg/kg) begins at a rate of 3 mg/kg per min followed by a continuous infusion at a rate of 1-2 mg/kg per hour.
Study: NCT04068337

Intervention type: PROCEDURE
Intervention: Aortic root replacement with Freestyle biological prosthesis with and without hemiarch replacement
Description: Aortic root replacement with Freestyle biological prosthesis. Some patients receive additional hemiarch replacement performing an open anastomosis to the aortic arch under antegrade cerebral perfusion through axillary artery. Comparison with patients, who were cannulated and perfused systemically

Intervention type: PROCEDURE
Intervention: Aortic root replacement with Freestyle biological prosthesis with and without hemiarch replacement
Description: Aortic root replacement with Freestyle biological prosthesis. Some patients receive additional hemiarch replacement performing an open anastomosis to the aortic arch under antegrade cerebral perfusion through axillary artery. Comparison with patients, who were cannulated and perfused systemically
Study: NCT01954979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: The study will follow a standard 3+3 design with two escalating doses of abatacept to determine the maximum tolerated dose (MTD): 3 mg/kg (dose level 1) and 10 mg/kg (dose level 2). Dose-limiting toxicities (DLTs) are defined as any Grade 3 or 4 toxicities judged to be probably or definitely related to abatacept.
Study: NCT00689767

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CINATRA™ Coronary Stent System
Description: Bare metal cobalt chromium stent implantation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CINATRA™ ISA 247 Coated Coronary Stent System
Description: Drug coated cobalt chromium stent implantation
Study: NCT01556373

Intervention type: OTHER
Intervention: NA : non interventional study
Description: NA : non interventional study

Intervention type: OTHER
Intervention: NA : non interventional study
Description: NA : non interventional study
Study: NCT02573974

Intervention type: OTHER
Group type: OTHER
Intervention: Samples
Description: Blood samples, muscle biopsy and sample of hair

Intervention type: OTHER
Group type: OTHER
Intervention: Samples
Description: Blood samples, muscle biopsy and sample of hair
Study: NCT01339754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabectedin
Description: 1.3 mg/mq as a 3 hour continuous infusion every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabectedin
Description: 1.3 mg/mq as a 3 hour continuous infusion every three weeks until progression
Study: NCT00546585

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/H7N7 Vaccine
Description: Monovalent subvirion H7N7 vaccine, 4 dose levels of vaccine, each subject will receive 2 doses (7.5, 15, 45, or 90 micrograms); the same dose will be given at Day 0 and Day 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/H7N7 Vaccine
Description: Monovalent subvirion H7N7 vaccine, 4 dose levels of vaccine, each subject will receive 2 doses (7.5, 15, 45, or 90 micrograms); the same dose will be given at Day 0 and Day 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/H7N7 Vaccine
Description: Monovalent subvirion H7N7 vaccine, 4 dose levels of vaccine, each subject will receive 2 doses (7.5, 15, 45, or 90 micrograms); the same dose will be given at Day 0 and Day 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/H7N7 Vaccine
Description: Monovalent subvirion H7N7 vaccine, 4 dose levels of vaccine, each subject will receive 2 doses (7.5, 15, 45, or 90 micrograms); the same dose will be given at Day 0 and Day 28.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline for injection (0.9%); 0.5 ml volume sodium chloride injection. Subjects will receive 2 doses on Day 0 and Day 28.
Study: NCT03210805

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Polyunsaturated Fatty Acids Supplementation
Description: 28 days of a commercially available supplement. 4 capsules per day.
Study: NCT04154956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR408701
Description: Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: IV infusion
Study: NCT05008146

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Baseline [C-11]NOP-1A PET Scan
Description: Radiotracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Intravenous, 1mg/Kg

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-hydrocortisone [C-11]NOP-1A PET Scan
Description: Radiotracer
Study: NCT00223860

Intervention type: DRUG
Group type: OTHER
Intervention: Human chorionic gonadotropin (hCG)

Intervention type: DRUG
Group type: OTHER
Intervention: Luteinizing hormone releasing hormone (LHRH)
Study: NCT05354050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DARE-BV1
Description: 2% Clindamycin 100 MG
Study: NCT01516047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1
Description: 125 mg to 2000 mg abiraterone acetate suspension on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2
Description: 2000 mg abiraterone acetate suspension on Day 1
Study: NCT04289818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: Health Coaching as face to face with a coach
Study: NCT03620344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADH-Me Book and ADHD Informational Brochure
Description: Understanding ADHD information brochure published by American Academy of Pediatrics and a children's book about ADHD condition

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: ADHD Informational Brochure Only
Description: Understanding ADHD information brochure published by American Academy of Pediatrics
Study: NCT00918411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT05319067

Intervention type: OTHER
Intervention: Stool sampling
Description: Stool sample taken at home 24 hours before hospital visit

Intervention type: OTHER
Intervention: Stool sampling
Description: Stool sample taken at home 24 hours before hospital visit

Intervention type: OTHER
Intervention: Stool sampling
Description: Stool sample taken at home 24 hours before hospital visit
Study: NCT04644250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Participants will also receive Toripalimab(240mg) VD 30 min on days 3, 24 and 45，3 cycles in total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome/Carboplatin
Description: Participants will receive carboplatin (AUC=2) VD 30min and paclitaxel liposome (50mg/m²) CIV 24h on day 3,10,17,24,31, 5cycles in total.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: A total of 41.4 Gy, 23 fractions of 1.8 Gy on Day 1 to 31.
Study: NCT01564550

Intervention type: DRUG
Intervention: Insulin
Description: Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.

Intervention type: DRUG
Intervention: insulin
Description: Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.

Intervention type: OTHER
Intervention: diet
Description: The subjects ingest a three day isocaloric diet (55 % carbohydrate,30% fat, 15 % protein)prior to the study day.

Intervention type: OTHER
Intervention: no diet
Description: The subjects will ingest a non-restricted diet prior to the study day.
Study: NCT00617760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)
Description: MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle, PCV7 (0.5 ml) to be administered in the right thigh muscle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)
Description: PCV7 (0.5 ml) to be administered in the right thigh muscle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT)
Description: MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle
Study: NCT00728390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: CP-751,871 at recommended dose on Day 1 and 2 of cycle 1, then on Day 1 every 3 weeks; and PF-00299804 orally at recommended dose once daily.
Study: NCT02965950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: I.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: I.v. infusion
Study: NCT04170738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall
Description: 3 weeks of Adderall
Study: NCT03128138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127
Description: Drug: SPH3127 Tablet~Drug: Placebo Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127
Description: Drug: SPH3127 Tablet~Drug: Placebo Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127
Description: Drug: SPH3127 Tablet~Drug: Placebo Tablet
Study: NCT02965950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: I.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: I.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: I.v. infusion
Study: NCT03229369

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Isolated anatomic ACL reconstruction
Description: Hamstrings free grafts using a two-incision intra-articular Anterior Cruciate ligament (ACL) reconstruction technique. Both ST and gracilis will be prepared with doubled strands, a standard quadrupled graft. The femoral tunnel will be performed in outside-in manner. The tibial tunnel will be drilled in the center of the ACL tibial footprint, sparing the ACL tibial stump, when possible. ACL graft will be first fixed in the femur and then in the tibia, both with an interference screw at 30 degrees of knee flexion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Anterior Cruciate Ligament and Anterolateral Ligament reconstruction
Description: Hamstrings free grafts using a two-incision ACL reconstruction with the addition of a gracilis prolongation for ALL reconstruction. ACL graft will exhibit a quadruple strand (tripled ST + single gracilis) and the ALL graft, a single strand with the gracilis prolongation. ALL tibial tunnel will be performed with a 5mm drill, 1cm distal to the articular level, midway from the fibular head and Gerdy Tubercle, crossing the tibia toward its anteromedial cortex, 1cm distal to the ACL tunnel. Femoral ACL and ALL tunnels are coincident and located posterior and proximal to the lateral epicondyle. Intra-articular surgery will be performed in the same manner as comparative group. Gracilis prolongation is routed through the tibial ALL tunnel and then retrieved in the anteromedial aspect of the tibia, 1cm distal to the ACL tunnel entrance. ALL is fixed in full extension and neutral rotation, tying both graft extremities with 3 knots.
Study: NCT03432975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine 10%
Description: The side of the mouth receiving the subgingival irrigations of povidone iodine 10% (test group)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: The other side of the mouth will be irrigated with a sterile saline solution (control group)
Study: NCT03128138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127
Description: Drug: SPH3127 Tablet~Drug: Placebo Tablet
Study: NCT04937868

Intervention type: OTHER
Intervention: There are no interventions associated with this study
Description: This study is purely observational, there will be no interventions or changes in care related to patient inclusion in this study.
Study: NCT01012830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huperzine A
Description: Huperzine A in 200 microgram (mcg) capsules taken twice daily for 8 weeks.
Study: NCT04049175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Tablet of CHF 6532
Study: NCT03128138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127
Description: Drug: SPH3127 Tablet~Drug: Placebo Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127
Description: Drug: SPH3127 Tablet~Drug: Placebo Tablet
Study: NCT04049175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Tablet of CHF 6532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Tablet of CHF 6532

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment D
Description: Tablet of CHF 6532 placebo
Study: NCT04315077

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oceanix®
Description: Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: 5 days of supervised and programmed whole-body resistance training.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Training
Description: 5 days of supervised and programmed whole-body resistance training.
Study: NCT02535273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: local anesthesia：0.67% lidocaine local anesthesia layer by layer to the periosteum at the puncture site，Establish puncture channel, injection 5ml 0.67% lidocaine into the vertebral body through the catheter, and observe 5-10min before operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: local anesthesia：0.67% lidocaine local anesthesia layer by layer to the periosteum at the puncture site，Establish puncture channel, injection 5ml 0.67% lidocaine into the vertebral body through the catheter, and observe 5-10min before operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: local anesthesia：0.67% lidocaine local anesthesia layer by layer to the periosteum at the puncture site，Establish puncture channel, injection 5ml 0.67% lidocaine into the vertebral body through the catheter, and observe 5-10min before operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: local anesthesia：0.67% lidocaine local anesthesia layer by layer to the periosteum at the puncture site，Establish puncture channel, injection 5ml 0.67% lidocaine into the vertebral body through the catheter, and observe 5-10min before operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Dexmedetomidine
Description: maintenance dose：Intravenous infusion of dexmedetomidine 0.3 μg/kg/min until the end of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderate-dose Dexmedetomidine
Description: maintenance dose：Intravenous infusion of dexmedetomidine 0.5 μg/kg/min until the end of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose Dexmedetomidine
Description: maintenance dose：Intravenous infusion of dexmedetomidine 0.7 μg/kg/min until the end of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Intravenous injection normal saline equal quantity，completed within 10 minutes. Intravenous infusion of normal saline 0.125 μg/kg/min until the end of surgery
Study: NCT03966833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPT-G
Description: 14 weeks of group-based interpersonal therapy (IPT-G)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPT-G
Description: 14 weeks of group-based interpersonal therapy (IPT-G)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unconditional Cash Transfer
Description: Lump sum cash transfer
Study: NCT04899830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telepresence robot
Description: From the application installed on a tablet, the patient hospitalized in a center for a period of at least 2 months can start from the center where he is hospitalized the mobile robotic telepresence assistance device installed at home to communicate with his family, his friends, his neighbors,...)
Study: NCT03958370

Intervention type: OTHER
Intervention: Fitbit
Description: Fitbit use during physical therapy session
Study: NCT04211038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inspiratory threshold load device
Description: Before experiment ,every subject use a flanged mouthpiece attached to a manually operated occlusion valve in order to measure maximal inspiratory pressure (MIP)at functional residual capacity .~And then, the healthy subjects will be increased the neural respiratory drive by increasing the pressure in a water-sealed inspiratory threshold loading device. At last, all subjects will do Incremental cycle ergometry test with the assisstance of NPPV.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inspiratory threshold load device
Description: Before experiment ,every subject use a flanged mouthpiece attached to a manually operated occlusion valve in order to measure maximal inspiratory pressure (MIP)at functional residual capacity .~And then, the healthy subjects will be increased the neural respiratory drive by increasing the pressure in a water-sealed inspiratory threshold loading device. At last, all subjects will do Incremental cycle ergometry test with the assisstance of NPPV.
Study: NCT02139033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retaine™
Study: NCT00568529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine and Oxaliplatin
Description: Capecitabine 1000mg/m2 Bid d1-14 Oxaliplatin 130mg/m2 d1 q3w
Study: NCT00740948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab (mabthera) Injection
Description: 2 \* 1g of Rituximab at the 1st day and at the 14th day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: NaCl 0.9% or Glucose 5%
Description: 2\* 250ml of NaCl 0.9% or Glucose 5% at the 1st day and at the 14th day.
Study: NCT01515410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM-1992
Description: 72.5mg carbidopa/230mg levodopa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinemet IR
Description: Immediate-release tablet containing 25mg carbidopa and 100mg levodopa
Study: NCT00353717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab paclitaxel
Description: weekly iv paclitaxel 80 mg/m2 and cetuximab 250 mg /m2
Study: NCT02212574

Intervention type: DRUG
Group type: OTHER
Intervention: Lomustine
Description: Chemotherapy Cycle A Lomustine (CCNU) is given by mouth on Day 1.

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: Chemotherapy Cycle A Vincristine is given directly into a vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1, 8, and 15.

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Chemotherapy Cycle A Cisplatin is given directly into a vein over 8 hours on Day 1.

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Chemotherapy Cycle B Cyclophosphamide is given into a vein over 1 hour on Days 1 and 2.

Intervention type: DRUG
Group type: OTHER
Intervention: Mesna
Description: Chemotherapy Cycle B MESNA, a drug to protect the bladder from the effects of cyclophosphamide, will be given 15 minutes before each dose of cyclophosphamide and repeated at 3 and 6 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: Chemotherapy Cycle B Vincristine is given directly into a vein directly into the vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1 and 8.
Study: NCT00443976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aurora kinase inhibitor AT9283
Description: The starting dose of AT9283 will be 1.5 mg/m2 given as a 24 hour IV infusion on Days 1 and 8 every three weeks.
Study: NCT04794803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reparixin
Description: Reparixin was administered via oral tablets 1200 mg TID for 7 days. In case of improvement, treatment can be prolonged at discretion of the investigator up to a maximum of 21 days of treatment in total or live discharge from the hospital, whichever comes first.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care